Abstract
Aptamers are short non-naturally occurring single stranded DNA or RNA able to bind tightly, due to their specific three-dimensional shapes, to a multitude of targets ranging from small chemical compounds to cells and tissues. Since their first discovery, aptamers became a valuable research tool and show great application to fundamental research, drug selection and clinical diagnosis and therapy. Thanks to their unique characteristics (low size, good affinity for the target, no immunogeneicity, chemical structures that can be easily modified to improve their in vivo applications), aptamers may represent a valid alternative to antibodies particularly for the treatment of neurological disorders that urgently need modalities for drug delivery through the blood brain barrier. Aptamers have excellent potential as reagents for the targeted delivery of active drug substances, either through direct conjugation to the aptamer, or through their encapsulation in aptamer-coated vesicles. We will review here the recent and innovative methods that have been developed and the possible applications of aptamers as inhibitors or tracers in neurological disorders and brain cancer.
Keywords: Alzheimer's disease, aptamers, blood-brain barrier, brain cancer, central nervous system, Parkinson's disease, prion diseases, SELEX
CNS & Neurological Disorders - Drug Targets
Title: Aptamers as Innovative Diagnostic and Therapeutic Agents in the Central Nervous System
Volume: 8 Issue: 5
Author(s): Vittorio de Franciscis, Carla Lucia Esposito, Silvia Catuogno, Luciano Cellai and Laura Cerchia
Affiliation:
Keywords: Alzheimer's disease, aptamers, blood-brain barrier, brain cancer, central nervous system, Parkinson's disease, prion diseases, SELEX
Abstract: Aptamers are short non-naturally occurring single stranded DNA or RNA able to bind tightly, due to their specific three-dimensional shapes, to a multitude of targets ranging from small chemical compounds to cells and tissues. Since their first discovery, aptamers became a valuable research tool and show great application to fundamental research, drug selection and clinical diagnosis and therapy. Thanks to their unique characteristics (low size, good affinity for the target, no immunogeneicity, chemical structures that can be easily modified to improve their in vivo applications), aptamers may represent a valid alternative to antibodies particularly for the treatment of neurological disorders that urgently need modalities for drug delivery through the blood brain barrier. Aptamers have excellent potential as reagents for the targeted delivery of active drug substances, either through direct conjugation to the aptamer, or through their encapsulation in aptamer-coated vesicles. We will review here the recent and innovative methods that have been developed and the possible applications of aptamers as inhibitors or tracers in neurological disorders and brain cancer.
Export Options
About this article
Cite this article as:
de Franciscis Vittorio, Esposito Lucia Carla, Catuogno Silvia, Cellai Luciano and Cerchia Laura, Aptamers as Innovative Diagnostic and Therapeutic Agents in the Central Nervous System, CNS & Neurological Disorders - Drug Targets 2009; 8 (5) . https://dx.doi.org/10.2174/187152709789542023
DOI https://dx.doi.org/10.2174/187152709789542023 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Spirulina paltensis: Food and Function
Current Nutrition & Food Science Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy
Current Genomics Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design Mechanisms of Prion Protein Aggregation
Protein & Peptide Letters Assessment In Vitro of a Novel Therapeutic Strategy for Glioma, Combining Herpes Simplex Virus HSV1716-mediated Oncolysis with Gene Transfer and Targeted Radiotherapy
Medicinal Chemistry Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science The Pharmacokinetics and Toxicology of Aluminum in the Brain
Current Inorganic Chemistry (Discontinued) Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Immunology Behind Tumors: A Mini Review
Current Cancer Therapy Reviews Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Current Cancer Drug Targets Biocompatible Micelles Based on Squalene Portions Linked to PEGylated Polyaspartamide as Potential Colloidal Drug Carriers
Current Nanoscience Epigenetic Therapies of Cancer
Current Cancer Therapy Reviews P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease
Current Pharmaceutical Design The Doublecortin Gene Family and Disorders of Neuronal Structure
Central Nervous System Agents in Medicinal Chemistry The Proline-Rich Domain and the Microtubule Binding Domain of Protein Tau Acting as RNA Binding Domains
Protein & Peptide Letters Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets MicroRNAs in Cancer Therapy: From Bench to Bedside
Current Cancer Therapy Reviews Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research